Investors

Presentations

2cureX presents at Redeye Fight Cancer

2CureX: CEO Fernando Andreu presents at Redeye Fight Cancer – January 19, 2023

2cureX presents its Q3 report

2cureX presents its Q3 report and answers questions in an online Q&A session. 24 November, 2022.

2cureX Strategy Deep-Dive

2cureX Strategy Deep-Dive presentation at RedEye, 15th November 2022.
In this Strategy Deep-Dive, 2cureX management discusses the company’s current position and ongoing strategy. With promising results from a recent market survey, and the deep understanding of the (path to) market we gained this year, our management team and other experts provide:
• A clear description of 2cureX’s ongoing strategy
• The market opportunity in colorectal cancer
• Feedback from the market
• Status of the execution of our strategy
• Future goals.

2cureX at RedEye "Investor AW"

2cureX: Fernando Andreu CEO presents at RedEye “Investor AW”, 31st March 2022, Malmø, Sweden.

2cureX at Life Science Investor Conference, ØU Life Science

2cureX: Fernando Andreu and Ole Thastrup presents at Life Science Investor Conference, ØU Life Science, 23th February 2022, Copenhagen.

Redeye Theme: Fight Cancer Seminar – Outlook 2022

2cureX: Fernando Andreu CEO presents at Redeye Theme, 24th January 2022, Copenhagen.

2cureX Company Introduction by HC Andersen Capital 2022

CSO and Founder Ole Thastrup presents at HC Andersen Capital, 13th January 2022, Copenhagen.

2cureX at HC Andersen Capital Virtual Growth Days 2021

CSO and Founder Ole Thastrup presents at HC Andersen Capital Virtual Growth Days 2021, 9th December 2021, Copenhagen (presentation in Danish).

2cureX at Redeye: Strategy Update

2cureX members of the management group present to investors, analysts, and media, 12th October 2021, Copenhagen.

Precision Oncology Webinar: Beyond Biomarkers

Clinical Peers (Dr. John Lindsay Marshall, from Georgetown University Hospital, US and Dr Jesús García-Foncillas, from University Hospital Fundación Jimenez Diaz, Madrid, Spain and Dr. Lars Henrik Jensen, University Hospital Vejle, DK) present the role of the functional test IndiTreat® in personalized oncology to oncologists and 2cureX’s Distributors.

2cureX at Redeye Growth Day 2021

2cureX: CEO Fernando Andreu presents at Redeye Growth Day 2021, 2nd June 2021, Copenhagen.

2cureX at Life Science Investor Conference, ØU Life Science

2cureX: Fernando Andreu and Ole Thastrup presents at Life Science Investor Conference, ØU Life Science, 26th May 2021, Copenhagen.

2cureX at Redeye Investor theme: Medtech & Diagnostics

2cureX CEO Fernando Andreu presents at Medtech & Diagnostics, Stockholm, 4th May 2021 virtual meeting.

2cureX at Redeye Investor Forum, 4th March 2021

2cureX: Fernando Andreu and Ole Thastrup presents at Investor Forum Online 4th May 2021, virtual meeting.
Download accompanying presentation

2cureX Nordnet Interview 2nd March 2021

2cureX CEO Fernando Andreu and CSO Ole Thastrup at Nordnet, 2nd March 2021, virtual meeting.
Download accompanying presentation

2cureX at Redeye Fight Cancer 2021

2cureX CEO Ole Thastrup presents at Fight Cancer 2021, 21st January 2021, virtual meeting.
Download accompanying presentation

2cureX at Redeye Life Science Day 2020

2cureX Ole Thastrup and Maarten van der Linden presents at Redeye Life Science Day 2020, 26th November 2020, Stockholm.

2cureX at Life Science Økonomisk Ugebrev

Ole Thastrup (2cureX CEO) and Maarten van der Linden (2cureX CBO) present at Life Science Økonomisk Ugebrev, 25th November 2020, Copenhagen.

2cureX at Danish Shareholders’ Association (Investor-Ugen)

Ole Thastrup (2cureX CEO) and Maarten van der Linden (2cureX CBO) give latest 2cureX outlook (2021-2023) at Danish Shareholders’ Association (Investor-Ugen), Copenhagen, November 12, 2020.
Download accompanying presentation

Benefits of IndiTreat® Sensitivity Test

Dr. Henrik Harling (2cureX CMO) discussing the dilemma facing the oncologist on the choice of first line colorectal cancer treatment.
Download accompanying presentation

IndiTreat® Sensitivity Test availability

Maarten van der Linden (2cureX CBO) talking about availability and application of IndiTreat® Sensitivity Test for colorectal, pancreatic and ovarian cancer patients.
Download accompanying presentation

2cureX presentation for investors

Ole Thastrup (2cureX CEO) and Maarten van der Linden (2cureX CBO) present 2cureX at Sedermeradagen in Copenhagen on March 11, 2020.

2cureX presentation for investors

Ole Thastrup (2cureX CEO) and Maarten van der Linden (2cureX CBO) present 2cureX at Sedermeradagen in Copenhagen, 2019.